<DOC>
	<DOCNO>NCT01164917</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled , two-period , crossover study approximately 20 subject Discoid Lupus Erythematosus enrol receive AMG 811 placebo one two sequence ( ie , AMG 811 follow placebo placebo follow AMG 811 ) .</brief_summary>
	<brief_title>Safety Study AMG 811 Subjects With Discoid Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Discoid</mesh_term>
	<criteria>Men woman , age 18 70 year age , inclusive , time randomization ; Diagnosis discoid lupus erythematosus ( DLE ) without SLE ; Intolerance antimalarial therapy ≥ 3 month antimalarial therapy residual disease activity . The total CLASI activity must ≥ 10 ; Stable dose topical steroid strong mediumpotency ( Class III less ) ≥ 2 week and/or systemic immunosuppressive therapy stable dose ≥ 8 week prior randomization ( except leflunomide require ≥ 12 week ) permit ; Oral prednisone ≤ 20 mg/day ( equivalent ) permit ; one increase one decrease ≤ 5 mg/day prednisone equivalent ( exceed 20 mg/day ) allow within 30 day randomization ; Any disorder ( include psychiatric ) , condition clinically significant disease ( diagnosis DLE SLE ) would , progressive nature and/or severity , interfere study evaluation , completion and/or procedure per investigator 's discretion ; History malignancy ; Signs symptom relevant history viral , bacterial , fungal , parasitic infection , recent history repeat infection ; Subjects evidence past active tuberculosis Positive serology HIV antibody , hepatitis B surface antigen hepatitis C antibody ( confirm PCR RIBA ) screen period ; Receipt live vaccine within 3 month study randomization study ; Prior use follow agent : Administration investigational biologic agent primarily target immune system Rituximab , LymphostatB , TAClIg within 9 month prior randomization ( comparable B cell deplete B cell inhibit biologics ) ; Rituximab ( deplete CD20 target agent ) treat patient must demonstrate return CD19+ B cell &gt; 5/μL ; CTLA4Ig within 3 month prior randomization ; Other agent within 5 halflives prior randomization ; Administration cyclosporine , tacrolimus , sirolimus , IV immunoglobulin , and/or plasmapheresis within 3 month randomization ; Administration thalidomide lenalidomide within 3 month randomization ; Administration oral IV cyclophosphamide ( alkylating agent ) within 9 month randomization ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Discoid Lupus</keyword>
	<keyword>Cutaneous Lupus</keyword>
</DOC>